Women`s Reproductive Disorders Therapeutics 2008-2018

Women`s Reproductive Disorders Therapeutics 2008-2018

Oral Contraceptive Market
The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods.
Although hormonal contraceptives are already a very mature market, visiongain believes that there is still room for further growth. In addition, modern basic research has identified some completely new approaches for the contraceptives of the future. Hormonal oral contraceptives will continue to play an important role in birth control from 2008 to 2018.
Lifecycle Management and Product Line Extension
The hormonal oral contraceptive market is undergoing both lifecycle management and product line extension of existing products in the market. There are progestin-only preparations and combined preparations containing an oestrogen and a progestin. Bayer Schering is developing a pill containing various forms of progestin. Clinical studies show that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria - a particularly severe form of the premenstrual syndrome (PMS), as well as on acne. Pills are increasingly being developed with reduced oestrogen dosages. Visiongain evaluates the prospects for extended or continuous administration of oral contraceptives. It is becoming popular for the treatment of endometriosis, dysmenorrhoea and menstrual-associated symptoms.
Menopause and Hormone Replacement Therapy
HRT has been the subject of considerable discussion recently. In light of recent and current studies, visiongain provides comprehensive market information on HRT market prospects from 2008 to 2018.
Women’s Reproductive Disorders Therapeutics, 2008-2018 examines that market critically, through comprehensive primary and secondary research. In addition to consultation with industry opinion, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based study with detailed financial analyses and informed opinion on the future of the women’s reproductive health market.
In particular, our new Women’s Reproductive Disorders Therapeutics, 2008-2018 report concentrates on the following essential aspects of that market:
• Overview of the women’s reproductive therapies market
• Key industrial players in the global women’s reproductive therapies market
• Forecasts of global market from 2008-2018, including forecasts of the leading therapeutic agents in this market area
• Forecasts for therapies in the seven leading pharmaceutical markets
• Drivers and opportunities in the global women’s reproductive therapies market
• Restraints and threats in the global women’s reproductive therapies market
• Primary research, with full interview transcripts
• Coverage of pipeline developments, with discussion of trends from the present onwards
Why You Should Buy This Report
In Women’s Reproductive Disorders Therapeutics, 2008-2018 you will receive the following essential information for understanding the women’s reproductive disorders therapeutics market and industry:
• The value of the women’s reproductive disorders therapeutics market and its principal market segments from 2008 to 2018
• Which current or future therapies that will drive the market for women’s reproductive disorders therapeutics from 2008 to 2018, with detailed sales forecasts
• Market drivers and restraints, including a comprehensive SWOT analysis for women’s reproductive disorders therapeutics
• The companies involved in the market and their business strategies
This Report would be Useful to the Following Professionals, Amongst Others:
• Business managers of pharmaceutical industry related to women’s reproductive disorders therapeutics
• Researchers, analysts and academics interested in women’s reproductive disorders therapeutics
• Senior staff in healthcare authorities relevant to women’s reproductive disorders therapeutics
• Investors in the pharmaceutical industry relevant to women’s reproductive disorders therapeutics
• Other interested business managers of multinational companies relevant to women’s reproductive disorders therapeutics
• Other business managers of domestic companies
• Academics, researchers and media

1 Executive Summary
1.1 Aims of the Report
1.2 Scope of the Report
2 Introduction to Reproductive Therapeutics
2.1 Mechanism of Action of Contraceptives
2.2 Combination Pills
2.2.1 Phasic Combination Pills
2.2.1.1 Monophasic Combination Pills
2.2.1.2 Biphasic Combination Pills
2.2.1.3 Triphasic Combination Pills
2.2.2 Regular Dose Combination Pills
2.2.3 Twenty Four-Day Packs
2.2.4 Extended Cycle Pills
2.2.5 Low Dose Combination Pills
2.2.6 High Dose Combination Pills
2.3 Progestin-Only Pills
2.4 Polycystic Ovarian Syndrome Medications
2.5 Oral Pills for Premenstrual Syndrome (PMS)
2.6 Hormonal Treatments for Endometriosis
2.7 Unwanted Pregnancy/Emergency Contraception
2.7.1 Plan B
2.7.2 Preven Faces Withdrawal from the Market in Favour of Plan B
2.8 Menopause and Improvement of Quality of Life with Hormone Replacement Therapy (HRT)
2.8.1 Wyeth's Premarin and Prempro for HRT
2.8.2 HRT for Prevention and Treatment of Osteoporosis
2.8.3 Natural Hormone Option for Breast Cancer Risk in Place of HRT
2.9 Folic Acid for Pregnant Women
2.10 Antiretroviral (ARV) Drugs Taken By HIV Positive Pregnant Women
2.10.1 Taking Zidovudine for the Prevention of Mother-To-Child Transmission of HIV
2.11 Artificial Insemination for HIV Positive Parent
2.12 Pregnancies Induced by Clomifene
2.13 Recombinant Gonadotropin for Female Infertility
2.14 Pelvic Inflammatory Disease Causes Infertility
2.15 Proprietary and Generic Contraceptive Pills
2.15.1 Warner Chilcott Received Patent Challenge on Oral Contraceptive
2.15.2 Bayer Schering Sues Watson Over Generic Yaz Application
2.15.3 Warner Chilcott Sues Watson Over Generic Femcon FE Application
2.15.4 Barr Attempts to Prevent Watson Marketing Seasonique
2.15.5 Patent Information for Hormonal Contraceptive Pills
2.16 Generic Clomifene Citrate as Fertility Medications
2.17 Natural Oestrogen To Treat Oestrogen-Dependent Disorders
2.18 Less Expensive Version of Premarin Not Available
3 Women’s Reproductive Disorders Therapeutics Market
3.1 World Hormonal Contraceptive Market
3.2 Major World Markets for Hormonal Contraceptives
3.2.1 Contraceptive Market Forecast for the US
3.2.2 Market Penetration for FDA-Approved Hormonal Contraceptives in Europe
3.2.3 Forecast for Hormonal Contraceptives in the UK
3.2.4 Forecast for Hormonal Contraceptives in Germany
3.2.5 Forecast for Hormonal Contraceptives in France
3.2.6 Marked Variation in Sales Forecasts between Italy's and Spain's Markets
3.2.7 Forecast for Contraceptive Use in Australia Shows Significant Growth Rate
3.2.8 Forecast for Contraceptive Use in Russia Shows High Growth Rate
3.2.9 Market Forecast for Highly Populated China
3.2.10 Contraceptive Market Forecast for Canada
3.2.11 Hormonal Contraceptive a Growing Market for Japan
3.3 Bayer Schering Dominates Global Market for Oral Contraceptives
3.4 Global Market for Hormonal Oral Contraceptives
3.4.1 Bayer Schering the Market Leader for Hormonal Oral Contraceptives
3.4.1.1 Yasmin was the Leading Product in the Market
3.4.1.2 Yaz and Loestrin 24 Fe Among Leading Products in the Market for Oral Contraceptives
3.4.1.3 Microgynon among the Highest Selling Oral Contraceptives
3.4.1.4 Meliane Marketed Internationally with High Sales Rating
3.4.2 Schering-Plough has a Significant Share in Hormonal Oral Contraceptive Market
3.4.2.1 Mercilon and Marvelon Listed Among Highest Selling Products without a US Market Penetration
3.4.2.2 Cerazette is an Oestrogen-Free Contraceptive with High Predicted Growth
3.4.3 Barr's Generic Product Tri-Sprintec has a Significant Market Share
3.5 Bayer Schering's Market for Hormonal Oral Contraceptives in the US
3.6 Both Proprietary and Generic Oral Hormonal Contraceptives Show Strong Growth
3.7 Other Hormonal Methods Pose Increased Competition for Hormonal Oral Contraceptives
3.7.1 NuvaRing's Growth Shows High CAGR
3.7.2 Setback in the Market for Contraceptive Patches
3.8 Depo-Provera to be Used for More than Two Years
3.9 Hormone Replacement Therapy Market Recovers
3.10 Types of Hormone Replacement Therapy
3.11 Market for Fertility Medications
3.12 Market for Folic Acid
4 SWOT Analysis for Hormonal Oral Contraceptive Market
4.1 SWOT Analysis for Hormonal Oral Contraceptive Market
4.2 Risk Analysis for Extended-Cycle Oral Contraceptive Market
4.3 Interview with Dr Heather Currie, NHS
4.3.1 Delivery System for Hormonal Oral Contraceptive
4.3.2 Transdermal Patch can be an Option for Some
4.3.3 Long-Acting Reversible Contraceptive as an Option
4.3.4 Extended Cycle Pills Provide Hope for Both Conception and Premenstrual Syndrome
4.3.5 New Hormonal Oral Contraceptive for European Market
5 SWOT Analysis for Hormone Replacement Therapy (HRT) Market
5.1 SWOT Analysis for Hormone Replacement Therapy (HRT) Market
5.2 Interview with Dr Heather Currie, Menopause Matters
5.2.1 Professionals to Make Informed Choices About HRT
5.2.2 Negative Publicity for HRT in the Recent Past
5.2.3 Signs of Hope Seen for HRT Market since Earlier Negative Publicity
5.2.4 Market for HRT Faced Difficulty After Study Results
5.2.5 Patients are Puzzled over Trial Results
5.2.6 HRT Market is Recovering since it Experienced a Slump
5.2.7 Patients are Opting for HRT after a Pause
5.2.8 Growth Will be Low from 2008 to 2018
5.2.9 Trial Has Begun for Younger Menopausal Age Group
5.2.10 Treatment Options for Menopause are Individualised
6 PEST Analysis for Undertaking Infertility Treatment
6.1 Social Analysis: Infertility Has an Impact on Society
6.2 Technological Analysis: Infertility Treatment Provides Hope for Many Couples
6.3 Technological Analysis: Usefulness of IVF or Intracytoplasmic Sperm Injection (ICSI)
6.4 Socio-Economic Analysis: Prevalence Rates for Infertility
6.5 Economic Analysis: Artificial Insemination Cheaper than IVF
6.6 Economic Analysis: Patients Seek Costly Private Sector IVF Treatment
6.7 Regulatory Affairs / Political Analysis: Guidelines for National Healthcare Service to be Reviewed
6.8 Interview with Dr Heather Currie, NHS Scotland
6.8.1 Clinical Trial with Fertility Medications
6.8.2 Lifestyle Management alongside Fertility Medications
6.8.3 NICE Recommendation for Age Limit for Fertility Treatment
6.8.4 Chlamydia Antibiotic Drug Becomes OTC
7 Research and Development (R&D) for Women’s Reproductive Disorders
7.1 R&D Products for Hormonal Contraception
7.2 Interview with Dr Heather Currie, NHS
7.2.1 Oral Contraceptive Pills Having Additional Therapeutic Effects
7.3 Bayer Schering Leading in R&D Products for Hormonal Contraception
7.3.1 Bayer Schering is Considering a Pill Containing Oestradiol in Place of Synthetic Ethinyl Oestradiol
7.3.2 Drospirenone in Yasmin and Yaz Have Additional Therapeutic Effects
7.3.3 Further Product Line Extension for Pills Containing Drospirenone
7.3.4 Bayer Schering's Improved Contraceptive Patch
7.3.5 Bayer Schering's Work on Male Pill
7.4 Studies Underway to Compare Individual Oral Hormonal Contraceptive with Yasmin
7.5 HRT Pipeline Information
7.5.1 Angeliq was a Follow-On Version of Yasmin for HRT Indication
7.6 Acquisition of Organon by Schering-Plough
7.7 Lifecycle Management of Organon's Fertility Medications
8 Conclusions
8.1 The Future Market for Hormonal Contraceptives
8.2 Mergers and Acquisitions
8.3 Lifecycle Management and Product Line Extension
8.4 The Menopause Market and Hormone Replacement Therapy
8.5 Future of Popular Fertility Medications
List of Tables
Table 2.1 List of HRT Medications According to Type of Hormone Used
Table 2.2 Patent Information for Hormonal Contraceptive Pills
Table 3.1 World Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.2 US Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.3 UK's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.4 Germany's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.5 France's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.6 Italy's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.7 Spain's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.8 Australia's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.9 Russian Fed.'s Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.10 China's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.11 Canada's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.12 Highest Selling Hormonal Oral Contraceptives, 2007/2008
Table 3.13 Yasmin Market Forecast, 2008-2018
Table 3.14 Yaz Market Forecast, 2008-2018
Table 3.15 Loestrin 24 Fe Market Forecast, 2008-2018
Table 3.16 Microgynon 30 Market Forecast, 2008-2018
Table 3.17 Mercilon Market Forecast, 2008-2018
Table 3.18 Marvelon Market Forecast, 2008-2018
Table 3.19 Cerazette Market Forecast, 2008-2018
Table 3.20 Highest Selling Systemic Hormonal Non-Oral Contraceptive Market, 2007/2008
Table 3.21 HRT Market Forecast, 2008-2018
Table 3.22 Highest-Selling Oestrogen Replacement Therapies, 2007/2008
Table 3.23 Highest-Selling Progestin-Only Therapies, 2007/2008
Table 3.24 Highest-Selling Combined HRT Therapies, 2007/2008
Table 3.25 Highest-Selling Androgen Therapies, 2007/2008
Table 3.26 High Selling Fertility Medications Market, 2007/2008
Table 3.27 Market for Folic Acid, 2007/2008
Table 4.1 SWOT Analysis for Hormonal Oral Contraceptive Market
Table 4.2, Risk Analysis for Extended-Cycle Oral Contraceptive Market
Table 5.1 SWOT Analysis for HRT Market
Table 7.1 Pipeline Products for Women's Reproductive Disorders
List of Figures
Figure 3.1 World Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.2 Major Market Revenue for Hormonal Contraceptives, 2007
Figure 3.3 Major Market Growth Rate for Hormonal Contraceptives in 2007
Figure 3.4 US Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.5 UK's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.6 Germany's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.7 France's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.8 Italy's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.9 Spain's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.10 Australia's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.11 Russian Fed.'s Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.12 China's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.13 Canada's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.14 Yasmin Market Forecast, 2008-2018
Figure 3.15 Yaz Market Forecast, 2008-2018
Figure 3.16 Loestrin 24 Fe Market Forecast, 2008-2018
Figure 3.17 Microgynon 30 Market Forecast, 2008-2018
Figure 3.18 Mercilon Market Forecast, 2008-2018
Figure 3.19 Marvelon Market Forecast, 2008-2018
Figure 3.20 Cerazette Market Forecast, 2008-2018
Figure 3.21 HRT Market Forecast, 2008-2018

Companies Listed
Abbott
Akzo-Nobel
Barr
Bayer Schering
Berlex
Cipla
Duramed
Ferring
Gruenenthal
Johnson & Johnson
Marion Merrell Dow
Mead Johnson
Mylan
Novartis
Novo Nordisk
Novogen
Organon
Ortho
Pfizer
Pharmacia
Sanofi-Aventis
Schering-Plough
Serono
Solvay
Upjohn
Warner Chilcott
Watson
Wyeth-Ayerst